Group 1 - The core viewpoint of the article highlights the continuous improvement in drug safety and the high-quality development of the pharmaceutical industry in the province, with a significant increase in the number of production enterprises [1] - By the end of 2025, the province had a total of 2,618 "two products and one device" (drugs, cosmetics, and medical devices) production enterprises, representing a 53% increase compared to 2020 [1] - The drug safety inspection pass rate remains above 99%, with no major drug safety incidents reported [1] Group 2 - In 2025, the province approved 107 new drug approval numbers, with 60 new varieties passing the consistency evaluation for generic drugs [2] - The first class 1 innovative drug "Azvudine tablets" and the first antibody drug "Bevacizumab injection" were approved during the "14th Five-Year Plan" period [2] - The provincial drug regulatory authority aims to create a new ecosystem for pharmaceutical industry development through five major actions, focusing on political guidance, reform innovation, drug safety, industry ecology, and regulatory capacity enhancement [2]

据介绍，辽宁医药产业既承载着服务国家战略、增进民生福祉的重要使命，也迎来了转型升级、跨越发 展的宝贵机遇。田东泉指出，面对新形势新任务，药监部门要以更大力度深化监管改革，为企业松绑减 负、激发创新活力；以更大力度加强法治建设，为企业提供公平公正、稳定可期的政策环境；以更大力 度强化服务保障，为企业提供便捷高效、精准可及的监管服务；以更大力度营造亲商重商氛围，为企业 提供开放包容、共赢共生的营商环境，当好产业发展的"服务员""护航员"。 田东泉强调，面对新机遇新挑战，辽宁省医药企业要专注主业、做优做强，筑牢高质量发展根基；要创 新突破、勇闯前沿，塑造产业竞争新优势；要严守法规、诚信经营，共建公平公正的市场生态；要心怀 大爱、奉献社会，在增进民生福祉中彰显担当，走好高质量发展之路，勇攀高峰、续写华章。 （文章来源：中国新闻网） 中新网沈阳2月2日电辽宁省药监与药企"面对面·心连心"座谈会2日在沈阳召开。 辽宁省药监局局长田东泉指出，过去的一年，辽宁省医药创新实力和质量显著提升，全国首台"光子计 数CT"落地辽宁，全球首创"心脏冷冻消融设备"在辽宁诞生，辽宁省医药制造业增加值增长4.1%，高于 辽宁省3.5个百分点 ...

王桂英在参加政协文化艺术界和体育界联组讨论时说，政府工作报告站位高远、求真务实，既客观 总结了2025年及"十四五"时期的发展成就，内容翔实、鼓舞人心；又科学谋划了"十五五"时期重要目标 和2026年重点任务，思路清晰、催人奋进。文化艺术和体育工作事关人民群众身心健康，对经济社会发 展具有重要作用，我们将持续强化政策集成，提升服务质效，为文艺体育事业发展营造良好生态。希望 各位委员充分发挥界别优势，深入挖掘齐鲁文化资源，生产和创造出更多群众喜闻乐见、市场广泛接受 的精品力作，更好满足人民群众的精神文化需求；一如既往关心支持竞技体育发展，积极做全民健身运 动的倡导者、参与者，持续激发体育消费潜力，推动文化强省、体育强省建设再上新台阶。 宋军继在参加德州代表团审议时说，政府工作报告总结成绩客观求实，设定目标科学务实，部署工 作精准扎实，体现了勇挑大梁的政治自觉，突显了识变应变的战略主动，彰显了真抓实干的工作作风， 展现了为民造福的深厚情怀，是一个主题鲜明、内容丰富、引领发展、催人奋进的好报告。"十五五"规 划纲要草案，通篇贯彻党的二十届四中全会和省委全会精神，是一个贯彻中央部署、顺应发展规律、契 合山东实际、反映 ...

Core Viewpoint - The Shandong Provincial Government has issued an implementation opinion aimed at deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry, marking a significant step in enhancing drug safety and industry development [1][2]. Group 1: Key Measures - The implementation opinion outlines 29 measures across six areas to strengthen the cultivation of pharmaceutical innovation, support cutting-edge technology, enhance innovation platform construction, and promote the transformation of innovative drugs and devices [2]. - It aims to optimize the clinical trial ecosystem by encouraging medical institutions to undertake trials, improving the efficiency of ethical reviews, promoting the application of AI technology, and enhancing institutional management and services [2]. - The reform of review and approval processes is emphasized, including proactive alignment with the National Medical Products Administration, support for generic drug services, and the promotion of smart regulation for traditional Chinese medicine [2]. Group 2: Promotion and Internationalization - The opinion promotes the clinical use of innovative products by establishing a catalog of innovative products, accelerating the listing process, and improving the medical insurance payment mechanism [2]. - It encourages the international development of the industry through targeted investment attraction, supporting the export of raw materials and formulations, and enhancing international cooperation [2]. - There is a focus on strengthening quality supervision throughout the entire process, ensuring corporate responsibility, enhancing smart regulatory capabilities, and cracking down on illegal activities [2].

Core Viewpoint - The Shandong provincial government is implementing comprehensive reforms in drug and medical device regulation to promote high-quality development in the pharmaceutical industry [1] Group 1: Policy and Strategic Initiatives - The Shandong Provincial Science and Technology Department is focusing on key technology breakthroughs and innovation platform construction to enhance the pharmaceutical industry's competitiveness [3] - The province plans to support nearly 1,000 major scientific innovation projects in the pharmaceutical sector by 2025, with over 300 million yuan in financial support [3] - The province has established 124 innovation platforms, including national and provincial key laboratories, to foster collaboration between leading enterprises and quality medical institutions [3] Group 2: Financial Support and Incentives - The government is increasing policy support for major innovative products, offering up to 40% of R&D investment as funding support for clinical trials, with maximum amounts of 10 million, 20 million, and 30 million yuan for different phases [4] - Over the past two years, 31 companies have received a total of 241 million yuan in R&D subsidies, effectively supporting the development of innovative drugs with strong efficacy and good industrialization prospects [4] Group 3: Future Directions - The provincial government aims to enhance the aggregation and allocation of innovation resources, including projects, platforms, and funding, to strengthen the technological support for high-quality development in the pharmaceutical industry [4][5] - Continuous efforts will be made to address the challenges in the pharmaceutical industry through various innovative approaches, including competitive bidding and targeted commissioning for key R&D tasks [4]

Core Viewpoint - The Shandong provincial government has issued a policy document aimed at enhancing drug and medical device regulation to promote high-quality development in the pharmaceutical industry, marking a significant step in reforming drug regulation and advancing the industry in the province [3]. Group 1: Policy Overview - The document titled "Implementation Opinions on Deepening Drug and Medical Device Regulation Reform to Promote High-Quality Development of the Pharmaceutical Industry" outlines 29 measures across six key areas [4]. - The initiative emphasizes the importance of drug and medical devices as critical goods for public health and economic development, reflecting the central government's commitment to drug safety [3]. Group 2: Key Measures - Strengthening the cultivation of pharmaceutical innovation by supporting cutting-edge technology, enhancing innovation platform construction, and promoting the transformation of innovative drugs and devices [4]. - Optimizing the clinical trial ecosystem by encouraging medical institutions to undertake trials, improving ethical review efficiency, and applying AI technology [4]. - Deepening review and approval reforms by aligning with national drug regulatory frameworks and enhancing the service system for drug production and innovation [4]. - Promoting the clinical use of innovative products by establishing a catalog of innovative products and improving the medical insurance payment mechanism [4]. - Encouraging international development of the industry through targeted investment attraction and enhancing international cooperation [4]. - Strengthening quality supervision throughout the process by enforcing corporate responsibility and enhancing smart regulatory capabilities [4].

转自：北京日报客户端 1月6日至7日，全国药品监督管理工作会议在北京召开。会议以习近平新时代中国特色社会主义思想为 指导，全面贯彻落实党的二十大和二十届历次全会精神，认真落实中央经济工作会议部署，总结2025年 和"十四五"药品监管工作，分析当前面临形势，部署2026年重点任务。市场监管总局党组书记、局长罗 文出席会议并讲话。市场监管总局党组成员，国家药监局党组书记、局长李利作工作报告。国家药监局 党组成员、副局长徐景和、黄果、雷平、杨胜，中央纪委国家监委驻市场监管总局纪检监察组负责同志 出席会议。 会议指出，2025年，全国药监系统认真落实习近平总书记"四个最严"要求，全面加强党的领导和党的建 设，全过程深化药品监管改革，全方位筑牢药品安全底线，全链条支持医药产业高质量发展，新批准创 新药和医疗器械数量创历史新高，全国药品安全形势保持总体稳定，人民群众对药品监管的获得感进一 步充实，为"十四五"时期药品监管改革发展画上圆满句号。五年来，药品监管部门服务国家区域发展战 略取得新进展，药品安全保障水平得到新提升，医药产业创新发展实现新跨越，药品监管国际话语权达 到新高度，监管现代化水平迈上新台阶，《"十四五"国 ...

Core Viewpoint - The implementation of the "Implementation Opinions" by the Shandong Provincial Government aims to enhance the innovation capability, optimize the industrial structure, and strengthen the international competitiveness of the pharmaceutical industry in Shandong [1]. Group 1: Specific Measures - The "Implementation Opinions" outlines 29 specific measures across six areas, focusing on strengthening pharmaceutical innovation, optimizing the clinical trial ecosystem, deepening review and approval reforms, promoting clinical application, advancing international development, and enhancing quality supervision [2][3]. Group 2: Key Features - The "Implementation Opinions" emphasizes a systematic integration approach, creating a comprehensive policy framework that spans from research and development to usage, innovation to regulation, and domestic to international [4]. - It highlights innovation-driven strategies, proposing specific measures such as research subsidies, strategic investments, and pilot support to foster key areas like cutting-edge technologies and platform development [4]. - The initiative aims to optimize the business environment by reforming review and approval processes, enhancing clinical trial ecosystems, and improving inspection efficiency to reduce institutional transaction costs [4]. - It reinforces clinical application by expediting the market entry of innovative products, standardizing pharmaceutical committee processes, and optimizing medical insurance payment policies [4]. - The focus on open development includes practical measures for internationalization, such as targeted investment attraction, support for overseas expansion, and international certification [4]. - The "Implementation Opinions" also stresses the importance of maintaining safety standards by ensuring accountability, enhancing smart supervision, and strictly combating illegal activities to guarantee the safety and efficacy of pharmaceuticals and medical devices [4].

中国青年报客户端讯（中青报·中青网记者刘言）第十届北京国际医药健康交流会暨京津冀医药产业协 同展示活动12月19日在北京市大兴区营商服务中心举行，来自京津冀三地的政府部门、科研机构、高等 院校、医疗机构、领军企业及行业组织的代表200余人，共同回顾发展成就、剖析时代挑战、擘画未来 蓝图，为推动医药健康产业创新协同与高质量发展凝聚广泛共识。 据介绍，本届大会以"擘画笃行，医药产业高质量发展新航程"为主题，旨在深入贯彻国家推动医药产业 高质量发展的战略部署，全面落实创新驱动发展要求，积极构建医药健康产业新生态，持续推动京津冀 协同发展迈向更高阶段。 河北省工业和信息化厅总工程师毛红领通过视频连线介绍了河北生物医药产业的发展成果。他表示，河 北省正以更大力度深化与京津合作，围绕生物医药产业发展需求，以企业为主体，联合高校、科研院所 组建创新联合体，整合各方资源，构建协同创新机制。 交流活动设置了"医药产业高质量发展"主场交流、"生物医药协同发展新征程"京津冀活动专场以及"多 元化发展的北京中药"中医药专场活动三个平行分论坛，与会专家、企业代表聚焦医疗器械创新监管、 京津冀生物医药协同发展以及推动中医药产业高质量发展 ...

Core Viewpoint - The article emphasizes the importance of drug safety and regulatory reforms in China, highlighting achievements during the 14th Five-Year Plan and outlining strategies for the 15th Five-Year Plan to enhance drug safety and support innovation in the pharmaceutical industry [1][2]. Achievements During the 14th Five-Year Plan - The national drug regulatory system has adhered to the "four strictest" requirements, leading to a stable drug safety situation and significant progress in building a strong pharmaceutical nation [2]. - Continuous strengthening of regulation has ensured drug quality and safety, with over 200,000 batches of drugs and 20,000 batches of medical devices tested annually, resulting in an overall drug inspection pass rate increase from 97.8% to 99.4% [2][3]. Innovation and Development Support - A series of measures have been implemented to promote innovation in the pharmaceutical and medical device sectors, with 220 innovative drugs and 282 innovative medical devices approved, marking increases of 6.2 times and 3.1 times, respectively, compared to the previous five-year period [3][4]. - The approval of 415 children's drugs and 155 rare disease drugs has further enhanced the vitality of innovation in the pharmaceutical industry [3]. Regulatory Capacity Enhancement - Revisions to key regulatory laws and the establishment of a comprehensive legal framework for drug regulation have been prioritized, alongside significant advancements in drug regulatory information technology [4]. - The establishment of specialized inspection centers and regional review centers has strengthened the capacity for drug regulation [4]. Transition to Proactive Drug Safety Management - The regulatory approach is shifting from "passive defense" to "active prevention," focusing on risk identification and responsibility enforcement to maintain drug safety [5][6]. - A dynamic safety supervision mechanism covering the entire lifecycle of drugs is being developed to address new challenges in product and technology innovation [5]. Support for Innovative Drug and Medical Device Development - The regulatory body aims to enhance the clinical value and technological content of innovative drugs and medical devices, supporting enterprises in their research and development efforts [7]. - Policies will be optimized to facilitate faster market entry for innovative products, including the implementation of a national drug standard improvement plan [8]. Ensuring Public Benefit from Regulatory Reforms - The regulatory work will prioritize enhancing public satisfaction and safety, ensuring that the benefits of reforms reach all citizens [9]. - Efforts will be made to expedite the approval of urgently needed drugs and improve the quality and efficacy of generic drugs [9]. Strengthening Social Cooperation and Public Awareness - Increased efforts in policy interpretation and public education on drug safety and regulatory measures are planned to enhance societal understanding and support for innovation in the pharmaceutical sector [10].